scispace - formally typeset
R

Risto Sankila

Researcher at International Agency for Research on Cancer

Publications -  103
Citations -  10971

Risto Sankila is an academic researcher from International Agency for Research on Cancer. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 54, co-authored 103 publications receiving 10509 citations.

Papers
More filters
Journal ArticleDOI

Increased relative risk of lung cancer in 2,904 patients with saccular intracranial aneurysm disease in eastern Finland.

TL;DR: Carriers of the sIA disease have an increased risk of developing lung cancer, and their long-term smoking habits after the first diagnosis should be elucidated for preventive purposes.

Incidence of cancer and statin usage-record linkage study

TL;DR: The consumption of statins (HMG-CoA reductase inhibitors) has been increasing, and a substantial part of the middle-aged and elderly population use them continuously because a large fraction of the population is exposed, even a small excess of risk with respect to cancer should be considered as discussed by the authors.
Journal ArticleDOI

Endothelial and epithelial expression of sialyl Lewis(x) in squamous carcinoma of the tongue.

TL;DR: Endothelial sLexexpression was significantly elevated in malignant lesions compared to normal tissues, but did not have any prognostic value for the relative survival rate, and epithelial s Lexexpression was decreased in carcinomas compared tonormal tongue.
Journal ArticleDOI

Relative survival of patients with prostate cancer as a first or subsequent tumor--a Nordic collaborative study.

TL;DR: The overall relative survival of patients with two primary cancers will be worse than those with a respective single cancer only, however, with a proper adjustment the subsequent cancer itself is not more fatal than a similar cancer as the only tumor of the patient.
Journal Article

LONG-TERM EXCESS MORTALITY IN 623 PATIENTS WITH BRAIN ARTERIOVENOUS MALFORMATIONS. Commentaries

TL;DR: AVMs are associated with long-term excess mortality that may be reduced by active, even partial, treatment and male patients have a higher excess mortality rate than female patients.